Roivant Sciences SEC Filings

Roivant Sciences (ROIV) reported Q2 FY2025 results with liquidity remaining strong and continued investment in its pipeline. Cash, cash equivalents and marketable securities were $4,385,835,000 as of September 30, 2025. Revenue was modest at $1,571,000 for the quarter.

Operating expenses were $307,804,000, including research and development of $164,568,000 and general and administrative of $143,125,000. The company recorded a change in fair value of investments of $(128,501,000) and interest income of $(45,341,000), resulting in a net loss attributable to Roivant of $(113,519,000) for the quarter. For the six months, the net loss attributable to Roivant was $(336,874,000).

The board authorized a new common share repurchase program of up to $500,000,000 on June 24, 2025, with no purchases under this program as of September 30, 2025. A prior $1,500,000,000 program was completed in June 2025, including a repurchase of 71,251,083 shares from Sumitomo for approximately $648,400,000. An at-the-market facility has $400,000,000 of capacity remaining. Common shares outstanding were 689,697,370 as of September 30, 2025, and 695,491,615 as of November 3, 2025.

Roivant Sciences (ROIV) furnished quarterly results via an 8‑K. The company reported that it issued a press release announcing financial results for the fiscal quarter ended September 30, 2025, which is attached as Exhibit 99.1. The disclosure under Item 2.02 is provided as “furnished,” not “filed,” and will only be incorporated into other filings if expressly referenced.

Roivant Sciences (ROIV): Officer Eric Venker reported an option exercise and same‑day sale. On 11/07/2025, he exercised 200,000 stock options at an exercise price of $3.85 per share (code M) and sold 200,000 common shares at a weighted average price of $20.22 (code S). Following these transactions, he reported 1,504,959 common shares beneficially owned directly and 6,076,523 derivative securities beneficially owned. The sales were made under a Rule 10b5‑1 trading plan adopted on March 28, 2025.

Venker is listed as President & Immunovant CEO. The options relate to an award with a vesting schedule beginning April 20, 2022, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, subject to continuous service.

Roivant Sciences (ROIV) director reported equity award. On 10/20/2025, a director acquired 1,056 Common Shares at $0, received as a fully vested grant under the Non-Employee Director Compensation Plan. After the award, the director beneficially owns 56,904 shares, held directly.

Roivant Sciences (ROIV) director James C. Momtazee reported routine equity activity on 10/20/2025. He received 789 Common Shares as a fully vested award under the company’s Non‑Employee Director Compensation Plan, recorded at $0 per share.

The company also executed a net settlement to cover taxes, withholding 158 shares at a price of $17.74. Following these transactions, Momtazee directly holds 108,543 Common Shares.

Roivant Sciences Ltd. (ROIV) reported insider activity by a director. On 10/20/2025, the director received 1,507 common shares under the Non-Employee Director Compensation Plan, which were fully vested on the grant date.

To cover tax withholding, the issuer executed a net settlement, withholding 281 shares at $17.74. After these transactions, the director directly owns 118,388 shares.

Roivant Sciences (ROIV) officer Eric Venker, President & Immunovant CEO, reported option exercises and open‑market sales. On 10/15–10/17/2025, he exercised 851,383 stock options at $15.85 and sold 851,383 common shares at weighted average prices of $16.93, $17.05, and $17.06, respectively. The transactions were executed under a Rule 10b5-1 trading plan adopted on March 28, 2025. Following these trades, he beneficially owns 1,504,959 common shares directly.

Roivant Sciences (ROIV) — Form 4 insider transaction: President & Immunovant CEO Eric Venker reported option exercises and same‑day sales under a Rule 10b5‑1 plan. On 10/09/2025, he exercised 104,940 stock options at $15.85 (Code M) and sold 104,940 Common Shares at a weighted average price of $16.30 (Code S). On 10/13/2025, he exercised 20,727 options at $15.85 and sold 20,727 shares at a weighted average price of $16.25.

Following these transactions, beneficial ownership of Common Shares was 1,504,959 (direct). The options exercised were part of awards with a vesting commencement date of December 27, 2019, now fully vested, and an expiration date of March 31, 2026. The reported sales were effected pursuant to a Rule 10b5‑1 trading plan adopted on March 28, 2025.

Roivant Sciences Ltd. (ROIV) filed a Notice of Proposed Sale under Rule 144 reporting the planned sale of 104,940 common shares (approximately 104,940 shares) with an aggregate market value of $1,710,040.33, scheduled for 10/09/2025 on NASDAQ. The filing states these shares were acquired via an options exercise on 10/09/2025 tied to a grant dated 03/26/2020, with payment by wire. The filer identifies prior sales by the same person totaling multiple transactions between 07/21/2025 and 10/08/2025, including several multi‑hundred‑thousand share disposals and gross proceeds listed per trade. The notice certifies the signer has no undisclosed material adverse information.